期刊
DRUG DISCOVERY TODAY
卷 21, 期 6, 页码 977-988出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2016.04.002
关键词
-
资金
- Novaliq GmbH, Germany
Cyclosporine A (CsA) has long been the mainstay treatment for dry eye syndrome (DES), one of the most common disorders of the eye. However, the poor water solubility of CsA renders it difficult to formulate it into topical ocular dosage forms. Restasis (R) is currently the only US Food and Drug Administration (FDA)-approved CsA formulation, while Ikervis (R) has recently been launched in Europe, with both commonly associated with severe ocular discomfort. Therefore, several CsA formulations have been investigated with the aim to improve bioavailability while reducing adverse effects associated with the marketed formulations. In this review, we summarize recent advances in ocular CsA delivery that provide safer and more effective alternatives for the management of DES and other ocular inflammatory conditions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据